List of Excipients in Branded Drug LEQVIO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	LEQVIO	inclisiran	0078-1000	PHOSPHORIC ACID	2034-08-18
Novartis Pharmaceuticals Corporation	LEQVIO	inclisiran	0078-1000	SODIUM HYDROXIDE	2034-08-18
Novartis Pharmaceuticals Corporation	LEQVIO	inclisiran	0078-1000	WATER	2034-08-18

# LEQVIO Excipient Strategy and Commercial Opportunities for Inclisiran

Last updated: August 11, 2026

LEQVIO is a long-acting subcutaneous small-interfering RNA drug containing inclisiran sodium. Its commercial differentiation comes from twice-yearly maintenance dosing, hepatic delivery through GalNAc conjugation, and administration in a prefilled syringe. The excipient system is comparatively simple: sodium chloride, phosphoric acid, sodium hydroxide, and water for injection. The strongest commercial opportunities are therefore not in discovering a new excipient, but in securing reliable pharmaceutical-grade supply, supporting sterile manufacturing, improving syringe and device performance, and developing differentiated follow-on formulations after core product protection weakens.

What is LEQVIO and how does its formulation work?

LEQVIO, or inclisiran, is an siRNA therapy that reduces hepatic production of proprotein convertase subtilisin/kexin type 9, or PCSK9. Reduced PCSK9 activity increases hepatic low-density lipoprotein receptor recycling and lowers LDL cholesterol.

The product is administered as a 284 mg subcutaneous dose initially, again at three months, and every six months thereafter. The drug is supplied as a single-dose 1.5 mL prefilled syringe containing inclisiran sodium equivalent to 284 mg of inclisiran.[1]

Inclisiran is conjugated to triantennary N-acetylgalactosamine, or GalNAc. The GalNAc ligand targets the asialoglycoprotein receptor on hepatocytes, supporting selective uptake into liver cells. This delivery mechanism reduces the need for complex nanoparticle or lipid-nanoparticle excipients used in some other nucleic-acid medicines.

What excipients are used in LEQVIO?

The United States prescribing information identifies the following inactive ingredients:

Component	Function in the formulation
Sodium chloride	Tonicity adjustment and ionic-strength control
Phosphoric acid	pH adjustment
Sodium hydroxide	pH adjustment
Water for injection	Vehicle

The formulation has a target pH near physiologic conditions. The label does not identify a lipid nanoparticle, polymeric carrier, surfactant, preservative, or cryoprotectant as part of the marketed injectable formulation.[1]

This low-excipient design reduces formulation complexity, but it does not eliminate manufacturing risk. The active ingredient is a chemically synthesized, highly charged oligonucleotide conjugate. Product quality depends on control of chain-length distribution, conjugation profile, aggregation, particulates, residual solvents, elemental impurities, bioburden, endotoxin, and container-closure compatibility.

What is the excipient strategy for LEQVIO?

LEQVIO uses a minimalist aqueous formulation designed to preserve the stability and injectability of a high-dose siRNA conjugate.

Why does LEQVIO use sodium chloride?

Sodium chloride provides tonicity control for subcutaneous administration. The excipient is widely available and supported by extensive injectable-product precedent. Its commercial value is based on consistency and regulatory acceptance rather than differentiation.

Potential quality attributes include:

• Low endotoxin burden
• Tight control of particulate matter
• High chemical purity
• Consistent osmolality
• Compatibility with the active siRNA conjugate
• Reliable supply in sterile injectable grades

Sodium chloride is unlikely to create a meaningful barrier to generic or follow-on competition by itself. It can, however, become a manufacturing constraint if a supplier experiences capacity, quality, or regional regulatory problems.

Why are phosphoric acid and sodium hydroxide used?

Phosphoric acid and sodium hydroxide are used to establish and maintain formulation pH. For an siRNA conjugate, pH control affects chemical degradation, aggregation, charge state, and syringe compatibility.

The commercial opportunity is concentrated in:

• High-purity pharmaceutical-grade reagents
• Validated sterile compounding processes
• Low-metal and low-particulate specifications
• Automated pH adjustment
• In-process monitoring
• Regional dual sourcing

Because both materials are commodity chemicals, they are unlikely to carry significant standalone pricing power. Suppliers can create value through validated grades, quality documentation, supply assurance, and integration into sterile manufacturing systems.

Why does LEQVIO not require a lipid nanoparticle?

Inclisiran uses GalNAc-mediated hepatocyte delivery. The conjugate directs the siRNA to liver cells without requiring the lipid nanoparticle systems used by several messenger RNA and siRNA products.

This reduces:

• Excipient count
• Formulation development complexity
• Potential immunogenicity associated with some delivery systems
• Manufacturing steps involving lipid mixing and particle-size control
• Cold-chain and colloidal-stability challenges associated with some nanoparticle products

The tradeoff is a high active-ingredient load. A 284 mg dose is substantially larger by mass than many conventional small-molecule injections, increasing the importance of syringeability, injection volume, concentration, and manufacturing yield.

What formulation challenges affect LEQVIO commercial manufacturing?

The primary formulation challenges are active-ingredient stability and delivery of a concentrated oligonucleotide dose through a subcutaneous route.

High-dose subcutaneous delivery

LEQVIO delivers 284 mg in 1.5 mL, creating a concentration of roughly 189 mg/mL before accounting for the exact salt and formulation basis. High concentration can increase viscosity and injection force.

This creates opportunities for:

• Low-friction syringe components
• Improved needle geometries
• Autoinjector or assisted-injection platforms
• Reduced injection-force systems
• Alternative high-concentration formulations
• Larger-volume delivery systems
• Sustained-release depots

Any reformulation must maintain bioequivalence or establish clinical comparability, preserve siRNA integrity, and avoid changing the pharmacokinetic profile or local tolerability.

Container-closure compatibility

The prefilled syringe is part of the product’s quality system. Critical considerations include:

• Adsorption of siRNA conjugate to glass or polymer surfaces
• Silicone oil interaction
• Tungsten and metal contamination from syringe manufacturing
• Extractables and leachables
• Needle-shield compatibility
• Plunger-stopper integrity
• Break-loose and glide forces
• Visible and subvisible particles

These attributes create commercial opportunities for syringe manufacturers, elastomer suppliers, silicone-control technologies, and container-closure testing laboratories.

Sterile manufacturing

The marketed product is an aqueous sterile injection. Sterile filtration, aseptic filling, fill-volume control, and particulate management are central process requirements.

Potential manufacturing-IP barriers include:

• High-concentration oligonucleotide filling
• Low-shear mixing
• Prevention of aggregation during hold times
• Aseptic filling into preassembled syringes
• In-line inspection
• Cold-chain control
• Yield improvement in siRNA synthesis and GalNAc conjugation

The highest-value manufacturing opportunities are likely to sit upstream of the final excipient blend, particularly in oligonucleotide synthesis, purification, conjugation, and sterile fill-finish.

What commercial opportunities exist for LEQVIO excipient suppliers?

The excipient market for LEQVIO is narrow but commercially defensible in several areas.

Pharmaceutical-grade commodity excipients

Sodium chloride, phosphoric acid, sodium hydroxide, and water for injection are available from multiple qualified suppliers. A supplier’s advantage will depend on:

• GMP manufacturing
• Global regulatory files
• Lot-to-lot consistency
• Audit history
• Sterile or low-endotoxin grades
• Supply continuity
• Regional manufacturing redundancy

Pricing pressure will remain high because the excipients are not unique and have broad pharmaceutical use.

Specialty excipient and formulation suppliers

The more attractive opportunity is to develop excipients or excipient systems that improve:

• Oligonucleotide stability
• Resistance to aggregation
• Syringeability
• Subcutaneous tolerability
• Storage stability
• Freeze-thaw robustness
• Container-closure compatibility

A new excipient would face a substantial regulatory burden. The commercial case is stronger where the excipient can be used across multiple siRNA, antisense, or peptide products rather than only LEQVIO.

Device and delivery-system suppliers

The 1.5 mL prefilled syringe creates a larger opportunity than the basic excipient package. Relevant technologies include:

• Low-force prefilled syringes
• Autoinjectors
• On-body delivery systems
• Needle-safety systems
• Silicone-reduced components
• Polymer syringes
• Human-factors engineering
• Administration systems for physician-office and specialty-pharmacy use

Because LEQVIO is administered by a health-care professional, device changes must address workflow, training, dose confirmation, storage, and administration time.

What is the FDA regulatory status of LEQVIO?

The FDA approved LEQVIO in December 2021 as an adjunct to diet and statin therapy for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, who require additional LDL-cholesterol lowering.[1]

In March 2023, the FDA expanded the indication to adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, who require additional lowering of LDL cholesterol. The label describes LEQVIO as an injection administered by a health-care professional.[2]

LEQVIO is a chemical drug product, not a biologic. Biosimilar regulation under the Public Health Service Act is therefore not the relevant pathway. Competitive products would generally involve abbreviated new drug application, 505(b)(2), or new drug application strategies, depending on the product’s active ingredient, formulation, delivery system, and claims.

What patent and exclusivity issues affect LEQVIO?

LEQVIO’s commercial protection is likely to rely on a combination of composition, siRNA sequence, GalNAc conjugation, formulation, manufacturing, use, and device-related rights. The relevant patent estate is broader than the four listed excipients.

Potential protection categories include:

Protection category	Commercial relevance
Inclisiran sequence and chemical structure	Protects the active siRNA or related conjugate
GalNAc conjugation	Protects hepatocyte-targeting architecture
PCSK9 gene-silencing methods	Supports method-of-use claims
Formulation and concentration	Can limit alternative injectable presentations
Manufacturing and purification	May raise process-development costs
Prefilled syringe and delivery device	Can delay device substitution
Dosing regimen	Supports twice-yearly administration claims

The FDA Orange Book should be reviewed for current listed patents and regulatory exclusivity. Patent expiration dates should be taken from the current Orange Book and underlying patent records rather than inferred from the approval date. A Paragraph IV challenge would depend on the patents listed for LEQVIO and the claims asserted by a challenger.

The product is not expected to face biosimilar competition. Its principal competitive risk is from alternative LDL-lowering products, future siRNA therapies, generic or follow-on inclisiran products, and products that offer easier administration or lower cost.

When does LEQVIO lose exclusivity?

LEQVIO’s exclusivity timeline has several components:

Protection type	General timing or issue
New chemical entity exclusivity	FDA approval date and applicable statutory term govern the period
Orphan-drug exclusivity	Depends on the approved indication and designation status
Patent protection	Determined patent by patent, including terminal disclaimers and patent-term adjustment
Pediatric exclusivity	Adds six months if granted
Formulation and method patents	May expire later than basic active-ingredient rights
Device protection	Can affect substitution without necessarily blocking an alternative drug

The practical loss-of-exclusivity date is the earliest point at which a legally viable competitor can obtain approval and launch without infringing enforceable claims. That date may differ from the expiration date of the earliest composition patent.

How does LEQVIO compare with competing LDL-lowering therapies?

LEQVIO competes with injectable and oral lipid-lowering products.

Product	Active ingredient	Administration	Delivery or formulation distinction
LEQVIO	Inclisiran	Initial dose, three-month dose, then every six months	GalNAc-siRNA in aqueous prefilled syringe
Repatha	Evolocumab	Every two weeks or monthly, depending on presentation	Monoclonal antibody, autoinjector or syringe
Praluent	Alirocumab	Typically every two or four weeks	Monoclonal antibody injection
Leqvio alternatives in development	Various siRNA or gene-silencing agents	Potentially infrequent dosing	May use GalNAc, lipid nanoparticles, or other delivery systems
Statins	Multiple small molecules	Daily oral dosing	Low-cost oral formulations
Bempedoic acid	Bempedoic acid	Daily oral dosing	Oral small molecule

LEQVIO’s key commercial advantage is administration frequency. Its main disadvantages are the need for a health-care professional, the high active-ingredient dose, and reimbursement sensitivity.

What generic entry risks exist for LEQVIO?

Generic-entry risk is likely to develop in stages.

First risk: therapeutic substitution

Oral generic statins and other low-cost lipid-lowering therapies already constrain pricing. Payers may require statin optimization before approving LEQVIO.

Second risk: competing branded injectables

PCSK9 monoclonal antibodies and next-generation RNA therapies can compete before an inclisiran follow-on product reaches the market. Their advantages may include established outcomes data, self-administration, or lower net cost.

Third risk: follow-on inclisiran

A follow-on product could seek approval through an abbreviated pathway if it can demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy FDA requirements. The most difficult issues may involve:

• Exact siRNA identity and impurity profile
• GalNAc conjugation equivalence
• Potency assay comparability
• Immunogenicity
• Pharmacokinetics and pharmacodynamics
• High-concentration subcutaneous delivery
• Prefilled-syringe performance
• Patent certification and litigation

A simple excipient substitution may not avoid patent claims directed to the active conjugate, dosing regimen, or manufacturing process.

What licensing and partnership opportunities are associated with LEQVIO?

The core product was developed through the Alnylam Pharmaceuticals and Novartis collaboration relating to inclisiran and RNA-interference technology. Alnylam’s RNAi platform and GalNAc delivery technology form part of the technical foundation for the product.[3]

Commercial opportunities for third parties include:

• Regional commercialization licenses
• Contract development and manufacturing
• Oligonucleotide synthesis
• GalNAc conjugation
• Sterile fill-finish
• Prefilled syringe supply
• Cold-chain logistics
• Specialty-pharmacy distribution
• Patient adherence and administration services
• Follow-on formulation development

The most defensible licensing assets are platform technologies that apply to several nucleic-acid products. A license limited to sodium chloride, phosphoric acid, or sodium hydroxide would have low strategic value unless it includes a validated formulation, manufacturing process, or device platform.

How strong is the LEQVIO formulation and manufacturing opportunity?

The formulation is relatively simple, but the product is technically demanding. This combination favors suppliers that can solve manufacturing and delivery problems rather than suppliers offering commodity excipients.

The strongest opportunities rank as follows:

1. Oligonucleotide and GalNAc manufacturing
2. High-concentration sterile fill-finish
3. Prefilled-syringe and injection-device systems
4. Stability-enhancing excipient platforms
5. Analytical methods for impurities, aggregates, and potency
6. Qualified commodity excipient supply

The commercial value of a formulation improvement will depend on whether it reduces cost, extends shelf life, supports room-temperature handling, improves injection performance, or enables self-administration. A change that only replaces one standard buffer component with another is unlikely to create durable differentiation.

Key Takeaways

• LEQVIO contains inclisiran sodium in an aqueous formulation with sodium chloride, phosphoric acid, sodium hydroxide, and water for injection.
• The product does not depend on a lipid nanoparticle; GalNAc conjugation directs siRNA delivery to hepatocytes.
• The excipient package is simple and largely commoditized.
• The main technical challenges are high-dose subcutaneous delivery, oligonucleotide stability, syringeability, particulates, and sterile fill-finish.
• The strongest commercial opportunities are in GalNAc-siRNA manufacturing, analytical control, container-closure systems, prefilled syringes, and administration devices.
• LEQVIO is a chemical drug, so biosimilar competition is not the relevant framework.
• Generic and follow-on risks will depend on the current Orange Book listings, patent claims, FDA pathway, formulation equivalence, and manufacturing capability.
• Patent protection may extend beyond the active ingredient to conjugation, dosing, formulation, manufacturing, and delivery-device claims.
• Licensing opportunities are more attractive for reusable nucleic-acid platforms than for individual commodity excipients.

FAQs

Does LEQVIO contain a lipid nanoparticle?

No. LEQVIO uses a GalNAc-conjugated siRNA design for hepatocyte targeting and has a simple aqueous formulation.

Can a manufacturer substitute the excipients in LEQVIO?

A substitution would require regulatory assessment, comparability data, stability evidence, and container-closure evaluation. Excipients that alter pH, osmolality, viscosity, aggregation, or injection performance could affect product quality.

What is the most valuable excipient opportunity for inclisiran?

The highest-value opportunity is likely a broadly applicable stability or delivery system for high-concentration oligonucleotide injectables. Commodity sodium chloride and pH-adjustment chemicals offer lower strategic value.

Could LEQVIO be reformulated for self-administration?

Potentially, but self-administration would require evaluation of injection volume, injection force, device usability, storage, dose accuracy, and human factors. A reformulation or new device could require a regulatory supplement or separate approval pathway.

Are there biosimilar versions of LEQVIO?

No biosimilar pathway applies because inclisiran is a chemically synthesized siRNA drug rather than a biological product. Competition would more likely involve a generic, follow-on, 505(b)(2), or alternative branded siRNA product.

References

1. U.S. Food and Drug Administration. (2021). LEQVIO (inclisiran) injection prescribing information. Novartis Pharmaceuticals Corporation.

2. U.S. Food and Drug Administration. (2023). LEQVIO approval history and prescribing information updates. FDA.

3. Alnylam Pharmaceuticals, Inc. (2013). Alnylam and Novartis enter global strategic alliance to advance RNAi therapeutics. Corporate announcement.